NEW YORK (AP) -- Biotechnology company BioTime Inc. on Thursday proposed two transactions that would combine its stem cell therapy assets with those of Geron Corp. In a letter to Geron shareholders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback